Ligand Pharmaceuticals Incorporated (LGND)
Jul 2, 2025 - LGND was delisted (reason: merged into PTHS)
113.30
+0.74 (0.66%)
Inactive · Last trade price on Jul 2, 2025
Ligand Pharmaceuticals Revenue
Ligand Pharmaceuticals had revenue of $47.63M in the quarter ending June 30, 2025, with 14.68% growth. This brings the company's revenue in the last twelve months to $187.58M, up 40.54% year-over-year. In the year 2024, Ligand Pharmaceuticals had annual revenue of $167.13M with 27.28% growth.
Revenue (ttm)
$187.58M
Revenue Growth
+40.54%
P/S Ratio
18.57
Revenue / Employee
$2,758,588
Employees
68
Market Cap
3.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
| Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
| Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
| Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
| Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLGND News
- 3 days ago - Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come - Seeking Alpha
- 8 days ago - Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance - GlobeNewsWire
- 17 days ago - Ligand to Participate in November Investor Conferences - GlobeNewsWire
- 19 days ago - Impax Small Cap Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 25 days ago - Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 4 weeks ago - Ligand to Host Investor Day on December 9, 2025 - GlobeNewsWire
- 5 weeks ago - Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients - GlobeNewsWire